Leo Pharma

Type: Company
Name: Leo Pharma
Web Address: http://www.leo.se
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Stop Paying Lip Service to Patient-Centricity

by Michael EdwardsPharma has operated the same way for 100 years, but the US healthcare model has changed completely in the last 30 years, for payers, pharmacists, hospitals, and even at the clinician level. These changes necessitate pharma – a traditionally ... [Published Pharmaceutical Executive - Apr 10 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Commercialisation ‘cools’ for biotech

Queensland has long espoused commercialising scientific research, but concerns exist about progress. Source: SuppliedA BIOTECHNOLOGY industry veteran has warned Queensland’s long-chased ambition of commercialising life sciences is slowing down.Industry ... [Published Brisbane Courier-Mail - Apr 07 2014]
First reported Apr 02 2014 - Updated Apr 03 2014 - 3 reports

Perrigo announces launch of plaque psoriasis drug

Perrigo Company plc, a provider of over-the-counter and generic prescription pharmaceuticals, has announced the launch of the authorized generic version of LEO Pharma A/S' Taclonex Ointment. Taclonex Ointment (calcipotriene 0.005% / betamethasone dipropionate ... [Published Individual.com - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Researchers Submit Patent Application, "Composition Comprising Lipid Nanoparticles and a Corticosteroid Or Vitamin D Derivative", for Approval

By a News Reporter-Staff News Editor at Biotech Week -- From Washington, D.C. , NewsRx journalists report that a patent application by the inventors Jensen, Louise Bastholm (Ballerup, DK); Petersson, Karsten (Ballerup, DK), filed on March 23, 2012 , was ... [Published 4 Traders - Apr 02 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 2 reports

Perrigo launches generic version of Taclonex ointment

Ireland-based Perrigo Company has started market launch and made its first shipments of the authorized generic version of LEO Pharma's Taclonex Ointment (calcipotriene 0.005% / betamethasone dipropionate 0.064%). ... [Published PBR - News - Apr 02 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

PICATO (Ingenol Mebutate) Gel [LEO Pharma Inc.]

Entities: Leo Pharma
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Antares Pharma Reports Fourth Quarter and Full Year 2013 Operating and Financial Results

By a News Reporter-Staff News Editor at Pharma Business Week Antares Pharma, Inc. (NASDAQ: ATRS) reported operating and financial results for the fourth quarter and full year ended December 31, 2013. Recent Highlights Received approval of OTREXUP (methotrexate) ... [Published Pharmacy Choice - Mar 24 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Data transparency debate: Europe decides its future

Transparency became a major issue in 2013 as various new pressure groups sprung up with the shared aim of forcing pharma companies to release their trial information.But whilst these groups have had much public exposure, what have been less visible - ... [Published Pharmafocus - Mar 24 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

ANTARES PHARMA : Announces LEO Pharma's Launch of OTREXUP Methotrexate Injection to Dermatologists for Adults with Psoriasis

By a News Reporter-Staff News Editor at Health & Medicine Week -- Antares Pharma, Inc. (NASDAQ: ATRS) announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate ... [Published 4 Traders - Mar 19 2014]
First reported Mar 13 2014 - Updated Mar 14 2014 - 3 reports

Antares Pharma : Reports Fourth Quarter and Full Year 2013 Operating and Financial Results

Recent HighlightsReceived approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration (FDA). OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable ... [Published 4 Traders - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 4 reports

Antares Earns Second OTREXUP Milestone

Antares Pharma, Inc. has received a second $5 million milestone payment from LEO Pharma in connection with the launch of OTREXUP. In November 2013, the companies entered an exclusive license and promotion agreement for OTREXUP (methotrexate) for symptomatic ... [Published Contract Pharma - Mar 12 2014]
First reported Mar 11 2014 - Updated Mar 12 2014 - 3 reports

Antares Pharma Receives Second Milestone Payment from LEO Pharma in OTREXUP Collaboration

EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement ... [Published CNBC - Mar 12 2014]

Quotes

...Intermountain Medical Center, Murray, and the University of Utah School of Medicine in Salt Lake City, writes in an accompanying editorial . "The risk of fatal thromboembolism stands on one side, and the risk of fatal bleeding lies just opposite."
Perrigo's Chairman, President and CEO Joseph C Papa stated, "This product was the result of the continued hard work and dedication of our Perrigo Rx team. This launch is another example of Perrigo's investment and commitment to making quality healthcare more affordable for consumers."
...Commenting on the development, Doug Suttles, Encana President & CEO said, "This transaction is consistent with our strategy. With the divestment of Jonah, we are unlocking value from a mature, high-quality asset and allowing our teams to focus on our five core growth areas and continue with execution of our new strategy." The full analyst notes on Encana Corporation are available to download free of charge at:
"Sandoz is proud to be first-to-market with a generic version of this important therapy," said Peter Goldschmidt, president of Sandoz US. "This launch further broadens our strong offering of differentiated generic dermatology products."

More Content

All (48) | News (42) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
The sultan of synthesis [Published RSC - Apr 11 2014]
Stop Paying Lip Service to Patient-Centricity [Published Pharmaceutical Executive - Apr 10 2014]
Fibrinolysis for Pulmonary Embolism Effective b... [Published American Journal of Public Health - Apr 10 2014]
Perrigo Announces Launch Of Authorized Generic ... [Published 4 Traders - Apr 10 2014]
Divestitures, New Drug Launches, Product Delive... [Published Finwin - Apr 08 2014]
Divestitures, New Drug Launches, Product Delive... [Published ADVFN India - Apr 08 2014]
Commercialisation ‘cools’ for biotech [Published Brisbane Courier-Mail - Apr 07 2014]
Perrigo launches generic Taclonex ointment to t... [Published PharmaBiz - Apr 03 2014]
Perrigo announces launch of plaque psoriasis drug [Published Individual.com - Apr 03 2014]
Perrigo launches generic version of Taclonex oi... [Published Big News Network - Apr 03 2014]
Generic Talconex now available [Published Drugtopics.com - Apr 03 2014]
Researchers Submit Patent Application, "Composi... [Published 4 Traders - Apr 02 2014]
Perrigo launches generic version of itchy skin ... [Published Kalamazoo Gazette - Apr 02 2014]
Sandoz introduces generic version of Leo Pharma... [Published Drug Store News - Apr 02 2014]
Perrigo launches generic version of Taclonex oi... [Published PBR - News - Apr 02 2014]
Perrigo announces first shipment of approved ge... [Published Individual.com - Apr 02 2014]
Perrigo ships authorized generic of Taclonex [Published Chain Drug Review - Apr 01 2014]
Perrigo Launches Authorized Generic Version Of ... [Published RTTNews.com - Apr 01 2014]
Perrigo : Announces Launch Of Authorized Generi... [Published 4 Traders - Apr 01 2014]
Research and Markets: Global Dermatological Dru... [Published BioMedReports - Mar 26 2014]
PICATO (Ingenol Mebutate) Gel [LEO Pharma Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 24 2014]
Antares Pharma Reports Fourth Quarter and Full ... [Published Pharmacy Choice - Mar 24 2014]
Data transparency debate: Europe decides its fu... [Published Pharmafocus - Mar 24 2014]
Organization supports clinical research in deve... [Published Orthopedics Today - Mar 21 2014]
ANTARES PHARMA : Announces LEO Pharma's Launch ... [Published 4 Traders - Mar 19 2014]
Court Report [Published JD Supra - Mar 18 2014]
Dermatological Drugs Market 2014 - 2018 Global ... [Published SBWire - Mar 17 2014]
Antares Pharma's CEO Discusses Q4 2013 Results ... [Published Seeking Alpha - Mar 17 2014]
Antares Pharma : Reports Fourth Quarter and Ful... [Published 4 Traders - Mar 14 2014]
Antares Pharma' CEO Discusses Q4 2014 Results -... [Published Seeking Alpha - Mar 13 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Perrigo launches generic version of Taclonex oi... [Published PBR - News - Apr 02 2014]
Ireland-based Perrigo Company has started market launch and made its first shipments of the authorized generic version of LEO Pharma's Taclonex Ointment (calcipotriene 0.005% / betamethasone dipropionate 0.064%). ...
PICATO (Ingenol Mebutate) Gel [LEO Pharma Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 24 2014]
Updated Date: Mar 24, 2014 EST ...
Antares Pharma Receives Second Milestone Paymen... [Published EON Science - Mar 12 2014]
EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the ...
Antares Pharma Receives Second Milestone Paymen... [Published Business Wire Science: Science News - Mar 12 2014]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement ...
Antares Pharma Receives Second Milestone Paymen... [Published Business Wire Health News - Mar 12 2014]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the achievement ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.